laryngectomy Biopsy

Biopsy

Report in 240Hrs

At Home

No Fasting Required

Details

Biopsy of larynx tissue.

₹888₹1,269

30% OFF

Laryngectomy Biopsy - Comprehensive Medical Test Guide

Why is it done?
- Histopathological examination of laryngeal tissue obtained during laryngectomy to confirm malignancy and determine tumor characteristics
- Primary indications: Suspected laryngeal cancer, persistent hoarseness unresponsive to treatment, unexplained voice changes lasting more than 2-3 weeks, visible laryngeal masses or ulcerations
- Assessment of surgical margins to ensure complete tumor removal and evaluate extent of disease
- Determination of tumor grade, stage, and histological type to guide treatment planning and prognosis
- Performed during surgical laryngectomy procedures when malignancy is suspected or confirmed preoperatively
Normal Range
- Normal Result: Benign laryngeal tissue with no malignant cells; normal stratified squamous epithelium; intact mucosal architecture without dysplasia
- Negative for Malignancy: Absence of carcinoma cells; may include benign pathology such as inflammation, infection, or hyperplasia
- Clear Surgical Margins: No malignant cells present at tissue margins; minimum distance typically ≥5mm from tumor edge is considered adequate
- Units of Measurement: Descriptive pathological diagnosis; tumor size in centimeters; histological grade (Grade 1-4); TNM staging system
Interpretation
- Squamous Cell Carcinoma (SCC): Most common laryngeal malignancy; graded as well-differentiated (G1), moderately differentiated (G2), or poorly differentiated (G3); associated with smoking and alcohol use
- Adenocarcinoma: Less common laryngeal malignancy; generally carries worse prognosis than SCC; requires different treatment approach
- Dysplasia: Graded as low-grade (LGDIN) or high-grade (HGDIN); indicates precancerous changes; HGDIN requires close follow-up and potential additional treatment
- Involved Margins: Presence of malignant cells at surgical edges; indicates incomplete tumor removal; predicts higher recurrence risk; may necessitate additional surgery or radiation therapy
- Lymph Node Involvement: Detection of metastatic disease in regional lymph nodes; indicates Stage III or IV disease; significantly affects prognosis and treatment decisions
- Factors Affecting Results: Smoking history, alcohol consumption, HPV infection status, prior radiation therapy, tissue fixation quality, pathologist expertise, specimen adequacy
- Immunohistochemistry (IHC): May include p16, HPV, p53 testing; positive HPV/p16 indicates HPV-related cancer with potentially different prognosis and treatment response
Associated Organs
- Primary Organ: Larynx (voice box) - located in the anterior neck; contains vocal cords and controls phonation, breathing, and swallowing protection
- Related Structures: Pharynx, trachea, esophagus, cervical lymph nodes, thyroid gland, neck soft tissues
- Laryngeal Cancer Characteristics: Accounts for approximately 20-25% of head and neck cancers; higher incidence in males; typically develops from mucosal epithelium
- Associated Diseases: Laryngeal carcinoma, vocal cord paralysis, laryngeal papillomatosis, reflux laryngitis, voice disorders, chronic laryngitis
- Potential Complications: Locoregional recurrence, distant metastasis (lung, liver, bone), recurrent laryngeal nerve damage, permanent voice loss, swallowing dysfunction, aspiration risk
- Metastatic Pathways: Regional lymph node spread first (cervical chain); then distant metastases to lungs, liver, and bone; vascular invasion predicts aggressive behavior
Follow-up Tests
- Imaging Studies: CT chest/abdomen/pelvis for metastasis screening; MRI neck for local recurrence assessment; PET-CT for staging and detecting occult disease
- Endoscopic Surveillance: Flexible laryngoscopy every 3-6 months for first 2 years post-treatment; annually thereafter; evaluates for local recurrence and second primary tumors
- Molecular Testing: HPV status; TP53 mutations; PD-L1 expression; DNA methylation patterns for prognostic and predictive information
- Adjuvant Therapy Assessment: Radiation oncology consultation if involved margins or advanced disease; chemotherapy consideration based on staging and risk factors
- Systemic Monitoring: Physical examination of head and neck region; palpation of cervical lymph nodes; assessment for distant metastatic disease
- Voice and Swallowing Assessment: Speech pathology evaluation; videofluoroscopy if aspiration concerns; quality of life questionnaires post-laryngectomy
- Immunotherapy Considerations: PD-L1 testing for potential checkpoint inhibitor therapy eligibility; increasingly used in recurrent/metastatic disease management
Fasting Required?
- Fasting Requirement: Yes - NPO (nothing by mouth) is required
- Fasting Duration: Typically 6-8 hours before surgery; specific requirements depend on anesthesia protocol and surgical facility guidelines
- Last Fluid Intake: Usually 2 hours before procedure; clear liquids may be allowed until 2 hours preoperatively per institutional protocol
- Medications to Avoid/Continue: Anticoagulants (warfarin, aspirin, clopidogrel) typically held 5-7 days prior; discuss with surgeon; continue essential cardiac/blood pressure medications with small sip of water
- Pre-procedure Preparation: Shower/bathe with antiseptic soap night before surgery; remove nail polish and makeup; arrange transportation as patient cannot drive post-anesthesia
- Additional Instructions: Report to facility 1-2 hours early; bring insurance/ID documents; informed consent review; anesthesia consultation; baseline vital signs; lab work may be required (CBC, BMP, coagulation studies)
- Special Considerations: Inform provider of allergies, prior anesthesia complications, sleep apnea, or cardiac/pulmonary comorbidities; coordinate with speech pathology for postoperative voice rehabilitation planning

How our test process works!